Hemoglobinopathies Market Report

WILMINGTON, DELAWARE, UNITED STATES, February 14, 2024 /EINPresswire.com/ -- Hemoglobinopathies Market was valued at $4.2 billion in 2021, and is projected to reach $7 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031. The hemoglobinopathies are group of inherited disorders carries from parents to offspring. Hemoglobinopathies occurs due to mutations in the gene of hemoglobin molecule. The two main types of hemoglobinopathies are hemoglobin (Hb) variant occurs due to hemoglobin gene mutation and thalassemia caused due to insufficient hemoglobin production. The various hemoglobinopathies, such as thalassemia, sickle cell disease, hemoglobin variant, and beta thalassemia give rise to various health problems. Furthermore, the health problems associated with the disease are blurred vision, heart problems, slowed growth, gallstones, spleen enlargement, and stroke. Increase in disease prevalence is the main factor for market growth.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Pfizer, Biogen Inc., Alnylam Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., Abbott Laboratories, Global Blood Therapeutics, Inc., Novartis AG, Merck & Co. Inc., Danaher Corporation, Prolong Pharmaceuticals LLC., CANTHERA DISCOVERY LTD., Sanofi S.A.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/487

The hemoglobinopathies market is segmented on the basis of type, therapy, distribution channel, and region. By type, it is segmented into thalassemia, sickle cell disease, and others. By therapy, the market is bifurcated into monoclonal antibody medication, ACE inhibitors, hydroxyurea, and others. By distribution channel, the market is fragmented into hospital pharmacy, online providers, and drug stores and retail pharmacy.

Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By type, the thalassemia segment was the highest revenue contributor to the market. In the coming days, the market is expected to accelerate as the thalassemia prevalence is increasing in newborn as well in adults. The growth of this segment is increased due to a strong approved medicine and other therapies in pipeline. Other diseases from this segment, such as sickle cell disease also contribute to the market growth.

By therapy, the monoclonal antibody medication segment was the highest revenue contributor to the market, due to sufficient medicines available for the treatment. Thalassemia shows the potent recovery by the monoclonal antibody medication. The market growth is driven by newly developed and approved therapies by the industry leaders.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲: https://www.alliedmarketresearch.com/purchase-enquiry/487

Furthermore, the hemoglobinopathies market is expected to increase rapidly due to the various new therapies are in the approval and development stages. The hemoglobinopathies market size is also advancing due to the expansion of the pharmaceutical and healthcare industries and DNA therapies. On the other hand, lack of effective treatments, unavailability of stem-cells, and their high cost are anticipated to restrain the expansion of the global hemoglobinopathies market trends. The need for hemoglobinopathies significantly decreased after the COVID-19 pandemic. The focus of medical professionals, governments and the general public has moved to containing the virus's spread as a result of the fatal virus's quick expansion. It consequently decreased the need for hemoglobinopathies therapy. People visited clinics and hospitals only if they had an emergency. As a result, the COVID-19 pandemic caused severe disruptions in the market for diagnosis and treatment of the hemoglobinopathies.

Coronavirus severe acute respiration syndrome (SARS-CoV-2) is an infectious disease caused by the novel coronavirus (COVID-19), which originated in the Wuhan district in China in the late 2019, and since has spread to 212 countries. The virus was initially referred to as “novel coronavirus 2019” (2019-nCoV) by the WHO, However, on February 11, 2020, it was given the official name of SARS-CoV-2 by the International Committee on Taxonomy of Viruses. WHO declared COVID-19 as pandemic on March 11, 2020, and by September 1, 2020, over 28.1 million people have been infected globally with over 909,000 deaths. COVID-19 symptoms include fever, cough, and shortness of breath.

Nearly all industries have been impacted by the global public health COVID-19 pandemic. As coronavirus crises sweep the globe and force healthcare organizations to devote the majority of their funds to fight COVID-19, the outbreak of COVID-19 has resulted in a significant decline in demand for the hemoglobinopathies market across several sectors, particularly the health and pharmaceutical sectors. The main cause of the interruptions experienced by patients getting treatment for hemoglobinopathies in hospitals was the risk of infection. The treatments for thalassemia and sickle cell disease requires hospitalization for blood transfusion and bone marrow transplantation, hence the market growth declined in this period. As a result, the COVID-19 outbreak is expected to slow down the global market growth for treatments of hemoglobinopathies, which will have a negative effect on the market's value in 2022 and beyond.

𝐀𝐕𝐄𝐍𝐔𝐄- 𝐀 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐁𝐚𝐬𝐞𝐝 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 (𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐨𝐧-𝐝𝐞𝐦𝐚𝐧𝐝, 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐢𝐜𝐢𝐧𝐠 𝐦𝐨𝐝𝐞𝐥) 𝐎𝐟𝐟𝐞𝐫𝐞𝐝 𝐛𝐲 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

𝐆𝐞𝐭 𝐚𝐧 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐥𝐢𝐛𝐫𝐚𝐫𝐲 𝐨𝐟 𝐫𝐞𝐩𝐨𝐫𝐭𝐬 𝐚𝐭 𝐚𝐧𝐲 𝐭𝐢𝐦𝐞 𝐟𝐫𝐨𝐦 𝐚𝐧𝐲 𝐝𝐞𝐯𝐢𝐜𝐞 𝐚𝐧𝐝 𝐚𝐧𝐲𝐰𝐡𝐞𝐫𝐞. 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬, 𝐟𝐨𝐥𝐥𝐨𝐰 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤: https://www.alliedmarketresearch.com/library-access

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
Hemoglobinopathies Market: https://www.alliedmarketresearch.com/hemoglobinopathies-market
Ventricular Assist Devices Market https://www.alliedmarketresearch.com/ventricular-assist-devices-market
Single-use Bioprocessing Material Market https://www.alliedmarketresearch.com/single-use-bioprocessing-material-market
Hemophilia Treatment Market https://www.alliedmarketresearch.com/hemophilia-treatment-market

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

David Correa

Wilmington, Delaware, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn